Kyowa Hakko debuts Poteligeo in Japan; co-promotes Minirinmelt with Ferring

29 May 2012

Japanese drugmaker Kyowa Hakko Kirin (TYO: 4151) says that it has launched Poteligeo (mogamulizumab) injection, a therapeutic antibody for patients with relapsed or refractory CCR4-positive adult T-cell leukemia-lymphoma (ATL), in Japan.

Poteligeo is a humanized monoclonal antibody produced by applying Potelligent technology which was developed exclusively by Kyowa Hakko Kirin. This product is the first antibody for which Kyowa Hakko Kirin has a New Drug Application approved, and is also the world's first Potelligent antibody approved for marketing. The drug binds to CCR4 that is expressed on the surface of ATL cells. Poteligeo was also granted an orphan drug designation for the treatment of CCR4-positive ATL by the Ministry of Health, Labor and Welfare.

Co-promotion of treatment for nocturnal enuresis

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK